Effects of butylphthalide sodium chloride on NIHSS and ADL scores in patients with acute cerebral infarction
Objective To explore the clinical effect of butylphthalide sodium chloride in the treatment of patients with acute cerebral infarction.Methods A total of 82 patients with acute cerebral infarction admitted from October 2022 to October 2023 were selected as the study objects,and the patients were divided into control group(n=41)and study group(n=41)by random drawing of medical record number envelope.The control group was treated with intravenous thrombolysis combined with symptomatic basic treatment,and the study group was treated with butylphthalide sodium chloride on the basis of the treatment plan of the control group.The neurological function,daily living ability,hemorheological indexes,cytokines and inflammatory factors levels were compared between the two groups.Results After treatment,the National Institutes of Health Stroke Scale(NIHSS)score of the study group was lower than that of the control group,and the Activities of Daily Living(ADL)score was higher than that of the control group(P＜0.05).After treatment,the erythrocyte aggregation index,whole blood viscosity and plasma viscosity in the study group were lower than those in the control group(P＜0.05).After treatment,the levels of endothelin-1(ET-1),N-terminal pro-brain natriuretic peptide(NT-proBNP),neuron specific enolase(NSE)and homocysteine(Hcy)in the study group were lower than those in the control group(P＜0.05).After treatment,the levels of tumor necrosis factor-α(TNF-α)and C-reactive protein(CRP)in the study group were lower than those in the control group(P＜0.05).Conclusion Butylphthalide sodium chloride in the treatment of patients with acute cerebral infarction can reduce neurological deficits,improve daily living ability,improve hemorheological indexes and cytokine levels,and reduce inflammatory response,which can be widely promoted and applied.
万方数据
维普
